Plain-English translation of NCT06476184 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new way of giving and chemotherapy to people with advanced ovarian cancer who have not responded as well as hoped to their initial treatment and were not able to have complete surgery. Instead of receiving the standard 3-week schedule, one group will receive a more intense weekly schedule of the same drugs over 3 cycles. The trial is comparing this new schedule to continuing with the standard approach to see which works better.
Some people with advanced ovarian cancer do not respond well enough to standard chemotherapy, especially if they cannot have complete surgery to remove all the cancer. This trial is testing whether giving the medication more frequently but in smaller doses (called dose-dense chemotherapy) might work better than the standard schedule for these patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will receive a new weekly schedule of chemotherapy ( every 3 weeks and weekly) over 3 cycles, while the other group will continue with the standard 3-week schedule. Both groups may also receive growth factor injections to help protect blood counts. You will have regular visits with your treatment team for chemotherapy, blood tests, and monitoring, and you will be followed to see how well the treatment works for you.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France